Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR4 known ✓ | O95977 | 1/20 | 0.34 |
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.34 |
| ▸ | S1PR1 known ✓ | P21453 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | CRHBP | P24387 | 2/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | CCR6 | P51684 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38002 | 0.98 | ALDH1A1 (0.42) | ALDH1A1MEN1KMT2AL3MBTL1ATM | |
| Formaldehyde SCHEMBL2941056 | 0.94 | ALDH1A1 (0.40) | ALDH1A1MEN1KMT2AL3MBTL1ATM | |
| Methyl Alcohol SCHEMBL27709287 | 0.92 | ATM (0.41) | ALDH1A1MEN1KMT2AL3MBTL1ATM | |
| Acetic Acid SCHEMBL8462148 | 0.91 | ATM (0.41) | ALDH1A1MEN1KMT2AL3MBTL1ATM | |
| Acetaldehyde SCHEMBL1704750 | 0.89 | ALDH1A1 (0.37) | ALDH1A1MEN1KMT2AL3MBTL1ATM | |
| Phosphoric Acid SCHEMBL27824259 | 0.89 | ALDH1A1 (0.37) | ALDH1A1MEN1KMT2AL3MBTL1ATM | |
| Sulfuric Acid SCHEMBL8936551 | 0.89 | MEN1 (0.38) | ALDH1A1MEN1KMT2AL3MBTL1ATM | |
| Alcohol SCHEMBL27523839 | 0.88 | ALDH1A1 (0.40) | ALDH1A1MEN1KMT2AL3MBTL1ATM | |
| Acetonitrile SCHEMBL1262524 | 0.88 | ALDH1A1 (0.36) | ALDH1A1MEN1KMT2AL3MBTL1ATM | |
| Thiourea SCHEMBL8854711 | 0.86 | ALDH1A1 (0.39) | ALDH1A1MEN1KMT2AL3MBTL1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107412438-B | Processing method of Chinese wolfberry compound traditional Chinese medicinal material | 青海九康中药饮片有限公司 | 2020-11-06 | — | — | CN | disclosed |
| CN-108828089-A | The method that derivatization HPLC-UV/Vis method measures 4- nitrobenzaldehyde in chloramphenicol or its preparation | 中国药科大学 | 2018-11-16 | — | — | CN | disclosed |
| CN-107412438-A | A kind of processing method of matrimony vine herbal mixture material | 青海九康中药饮片有限公司 | 2017-12-01 | — | — | CN | disclosed |
| CN-107188825-A | A kind of preparation method of 2,4 dinitro benzene hydrazine hydrochloride | 李博强 | 2017-09-22 | — | — | CN | disclosed |
| EP-2366699-B1 | 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORP (JP) | 2013-08-07 | — | — | EP | disclosed |
| US-8304443-B2 | Indazole derivatives | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-11-06 | — | — | US | disclosed |
| US-8299055-B2 | 8-substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20120225909-A1 | INDAZOLE ANALOG | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-09-06 | — | — | US | disclosed |
| EP-2292592-B1 | SULFONAMIDE COMPOUND AND APPLICATION THEREOF | ASAHI KASEI PHARMA CORP (JP) | 2012-09-05 | — | — | EP | disclosed |
| EP-2484668-A1 | INDAZOLE ANALOGUE | Asahi Kasei Pharma Corporation (JP) | 2012-08-08 | — | — | EP | disclosed |
| US-20100022601-A1 | SULFONAMIDE COMPOUNDS AND THE USE | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-01-28 | — | — | US | disclosed |
| CN-101292162-A | Methods of Identifying Therapeutic Agents | SCRIPPS RESEARCH INST (US) | 2008-10-22 | — | — | CN | disclosed |
| CN-1878787-A | Detection of cholesterol ozonation products | SCRIPPS RESARCH INST (US) | 2006-12-13 | — | — | CN | disclosed |
| CN-1875030-A | Ozonation products of cholesterol for the treatment and prevention of atherosclerosis and/or cardiovascular disease | SCRIPPS RES INSITTUTE (US) | 2006-12-06 | — | — | CN | disclosed |
| CN-1788786-A | Submicroemulsion composition for injection and preparation process thereof | ZHANG WENFANG (CN) | 2006-06-21 | — | — | CN | disclosed |
| CN-1785415-A | Xingnaojing injection agent for refreshment and its preparation method | ZHANG WENFANG (CN) | 2006-06-14 | — | — | CN | disclosed |
| CN-1634501-A | Xingnaojing injection and preparation method thereof | ZHANG WENFANG (CN) | 2005-07-06 | — | — | CN | disclosed |
| CN-1634454-A | 'Xingnaojing' freeze dried | ZHANG WENFANG (CN) | 2005-07-06 | — | — | CN | disclosed |
| US-6376546-B1 | ANTIALLERGENS | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2002-04-23 | — | — | US | disclosed |
| EP-1024130-A1 | BIPHENYL-5-ALKANOIC ACID DERIVATIVES AND USE THEREOF | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 2000-08-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225909-A1 | INDAZOLE ANALOG | ADRB3, ADRB1, ADRB2 | S1PR4 2999/4885HSP90AA1 1305/4885S1PR1 2400/4885 |
| US-20100022601-A1 | SULFONAMIDE COMPOUNDS AND THE USE | PTH1R, CASR, SOST | S1PR4 634/4885HSP90AA1 2914/4885S1PR1 638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.